|
Abstract:
|
The increasing prevalence of drug resistant cancers necessitates further research and treatment development, raising a critical concern: is there a way to identify therapeutic strategies to intercept disease progression, and capture mechanisms prior to its development? We propose a novel approach to leverage metabolic stresses unique to cancer subtypes and molecular characteristics to complement common targeting. These metabolic processes span metabolic pathways and those that are associated with immune modulation. To further improve efficacy and clinical translation, it's imperative to understand which metabolic processes are most dysregulated at each stage of progression. We have developed a pipeline to determine which metabolic pathways are most dysregulated based on analysis of transcriptomic data. Additionally, we have identified Master Regulators of these dysregulated pathways, providing novel targets of adaptive response that may enhance efficacy of treatment. These findings provide a novel understanding of pathways highly dysregulated in unique cancers and how these pathways differ with molecular subtypes within a particular cancer.
|
